Symbols / GNPX Stock $0.93 -0.53% Genprex, Inc.

Healthcare • Biotechnology • United States • NCM
GNPX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Ryan M. Confer M.S.
Exch · Country NCM · United States
Market Cap 8.37M
Enterprise Value 580.86K
Income -16.23M
Sales —
FCF (ttm) -10.23M
Book/sh 2.42
Cash/sh 0.87
Employees 13
Insider 10d —
IPO Mar 29, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.42
PEG —
P/S —
P/B 0.38
P/C —
EV/EBITDA -0.04
EV/Sales —
Quick Ratio 3.60
Current Ratio 3.84
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -17.40
EPS next Y -2.18
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-05-12
Earnings (prior) 2025-05-12
ROA -135.78%
ROE -3.39%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 9.04M
Shs Float 9.02M
Insider Own 1.14%
Instit Own 0.74%
Short Float 5.59%
Short Ratio 1.40
Short Interest 505.52K
52W High 55.00
vs 52W High -98.32%
52W Low 0.90
vs 52W Low 2.79%
Beta -0.67
Impl. Vol. —
Rel Volume 0.77
Avg Volume 1.04M
Volume 797.94K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.93
Price $0.93
Change -0.53%
About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.93
Latest analyst target
3. DCF / Fair value
$-20.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.93
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-05-17 reit HC Wainwright & Co. Buy → Buy $10
2024-05-15 reit HC Wainwright & Co. Buy → Buy $10
2024-04-04 reit HC Wainwright & Co. Buy → Buy $10
2024-04-03 reit HC Wainwright & Co. Buy → Buy $10
2024-03-25 init HC Wainwright & Co. — → Buy $10
News
RSS: Latest GNPX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-14 LONGNECKER BRENT MICHAEL Director — 18 $1.23 $22
2025-12-22 LONGNECKER BRENT MICHAEL Director — 9,000 $0.00 $0
2025-12-22 BERGER MARK STANLEY Officer — 28,500 $0.00 $0
2025-12-22 CONFER RYAN M. Chief Executive Officer — 45,000 $0.00 $0
2025-12-22 MORENO TOSCANO JOSE ANTONIO Director — 9,000 $0.00 $0
2025-12-22 WILSON WILLIAM R. JR Director — 9,000 $0.00 $0
2024-12-05 LONGNECKER BRENT MICHAEL Director — 4,750 — —
2024-12-05 BERGER MARK STANLEY Officer — 18,250 — —
2024-12-05 CONFER RYAN M. Chief Executive Officer — 29,375 — —
2024-12-05 MORENO TOSCANO JOSE ANTONIO Director — 4,750 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
15.52
-26.72%
21.17
-31.82%
31.06
+30.32%
23.83
Research And Development
9.43
-10.50%
10.54
-40.20%
17.62
+53.05%
11.51
Selling General And Administration
6.09
-42.75%
10.63
-20.81%
13.43
+9.19%
12.30
General And Administrative Expense
6.09
-42.75%
10.63
-20.81%
13.43
+9.19%
12.30
Other Gand A
6.09
-42.75%
10.63
-20.81%
13.43
+9.19%
12.30
Total Expenses
15.52
-26.72%
21.17
-31.82%
31.06
+30.32%
23.83
Operating Income
-15.52
+26.72%
-21.17
+31.82%
-31.06
-30.32%
-23.83
Total Operating Income As Reported
-15.52
+26.72%
-21.17
+31.82%
-31.06
-30.32%
-23.83
EBITDA
-15.49
+26.61%
-21.10
+32.01%
-31.04
-30.40%
-23.81
Normalized EBITDA
-15.49
+26.61%
-21.10
+32.01%
-31.04
-30.40%
-23.81
Reconciled Depreciation
0.00
-100.00%
0.01
-55.39%
0.02
-41.33%
0.03
EBIT
-15.49
+26.63%
-21.11
+32.02%
-31.06
-30.32%
-23.83
Net Income
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Pretax Income
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Net Non Operating Interest Income Expense
-0.74
0.00
-100.00%
0.22
+138.75%
0.09
Interest Expense Non Operating
0.74
0.00
—
—
Net Interest Income
-0.74
0.00
-100.00%
0.22
+138.75%
0.09
Interest Expense
0.74
0.00
—
—
Interest Income Non Operating
—
0.06
-70.45%
0.22
+138.75%
0.09
Interest Income
—
0.06
-70.45%
0.22
+138.75%
0.09
Other Income Expense
0.03
-57.78%
0.06
+437.35%
-0.02
—
Other Non Operating Income Expenses
0.03
-57.78%
0.06
+437.35%
-0.02
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Net Income From Continuing Operation Net Minority Interest
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Net Income From Continuing And Discontinued Operation
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Net Income Continuous Operations
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Normalized Income
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Net Income Common Stockholders
-16.23
+24.12%
-21.39
+30.69%
-30.86
-29.99%
-23.74
Otherunder Preferred Stock Dividend
0.00
-100.00%
0.28
—
—
Diluted EPS
-17.40
+93.48%
-266.89
-1083.02%
-22.56
+97.72%
-990.00
Basic EPS
-17.40
+93.48%
-266.89
-1083.02%
-22.56
+97.72%
-990.00
Basic Average Shares
0.93
+1063.89%
0.08
-94.14%
1.37
+14.09%
1.20
Diluted Average Shares
0.93
+1063.89%
0.08
-94.14%
1.37
+14.09%
1.20
Diluted NI Availto Com Stockholders
-16.23
+24.12%
-21.39
+30.69%
-30.86
-29.99%
-23.74
Depreciation Amortization Depletion Income Statement
0.00
-100.00%
0.01
-55.39%
0.02
-41.33%
0.03
Depreciation And Amortization In Income Statement
0.00
-100.00%
0.01
-55.39%
0.02
-41.33%
0.03
Depreciation Income Statement
0.00
-100.00%
0.01
-55.39%
0.02
-41.33%
0.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
10.16
+146.32%
4.12
-61.35%
10.67
-57.46%
25.09
Current Assets
8.36
+302.26%
2.08
-72.42%
7.53
-64.92%
21.47
Cash Cash Equivalents And Short Term Investments
7.83
+388.92%
1.60
-76.23%
6.74
-67.85%
20.95
Cash And Cash Equivalents
7.83
+388.92%
1.60
-76.23%
6.74
-67.85%
20.95
Cash Financial
7.83
+388.92%
1.60
—
20.95
Receivables
—
—
0.00
-100.00%
0.03
Accounts Receivable
—
—
0.00
-100.00%
0.03
Prepaid Assets
—
—
—
—
Other Current Assets
0.53
+10.53%
0.48
-40.09%
0.79
+64.00%
0.48
Total Non Current Assets
1.80
-11.95%
2.05
-34.79%
3.14
-13.10%
3.61
Net PPE
0.00
0.00
-100.00%
0.01
-65.88%
0.02
Goodwill And Other Intangible Assets
—
0.00
-100.00%
0.77
+10.17%
0.70
Other Intangible Assets
—
—
0.77
+10.17%
0.70
Non Current Prepaid Assets
—
0.00
-100.00%
0.01
-54.17%
0.02
Other Non Current Assets
1.80
-11.95%
2.05
-12.81%
2.35
-18.06%
2.86
Total Liabilities Net Minority Interest
2.20
-12.26%
2.50
-23.05%
3.25
+15.80%
2.81
Current Liabilities
2.17
-13.16%
2.50
-23.05%
3.25
+15.80%
2.81
Payables And Accrued Expenses
0.74
-30.83%
1.07
-23.13%
1.40
+215.54%
0.44
Payables
0.74
-30.83%
1.07
-23.13%
1.40
+215.54%
0.44
Accounts Payable
0.74
-30.83%
1.07
-23.13%
1.40
+215.54%
0.44
Other Current Liabilities
1.43
+0.12%
1.43
-22.98%
1.86
-21.58%
2.37
Total Non Current Liabilities Net Minority Interest
0.02
0.00
0.00
0.00
Stockholders Equity
7.96
+391.43%
1.62
-78.15%
7.42
-66.70%
22.27
Common Stock Equity
7.96
+391.43%
1.62
-78.15%
7.42
-66.70%
22.27
Capital Stock
0.00
+1416.59%
0.00
-85.40%
0.00
+23.52%
0.00
Common Stock
0.00
+1416.59%
0.00
-85.40%
0.00
+23.52%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
2.32
-78.65%
10.86
+630.91%
1.49
+23.55%
1.20
Ordinary Shares Number
2.32
-78.65%
10.86
+630.91%
1.49
+23.55%
1.20
Additional Paid In Capital
178.99
+14.43%
156.42
+10.85%
141.10
+12.79%
125.10
Retained Earnings
-171.03
-10.48%
-154.80
-15.79%
-133.69
-30.01%
-102.83
Total Equity Gross Minority Interest
7.96
+391.43%
1.62
-78.15%
7.42
-66.70%
22.27
Total Capitalization
7.96
+391.43%
1.62
-78.15%
7.42
-66.70%
22.27
Working Capital
6.18
+1548.82%
-0.43
-109.98%
4.28
-77.08%
18.66
Invested Capital
7.96
+391.43%
1.62
-78.15%
7.42
-66.70%
22.27
Net Tangible Assets
7.96
+391.43%
1.62
-75.61%
6.64
-69.21%
21.57
Tangible Book Value
7.96
+391.43%
1.62
-75.61%
6.64
-69.21%
21.57
Derivative Product Liabilities
0.02
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-15.31
+14.57%
-17.92
+27.55%
-24.74
-40.39%
-17.62
Cash Flow From Continuing Operating Activities
-15.31
+14.57%
-17.92
+27.55%
-24.74
-40.39%
-17.62
Net Income From Continuing Operations
-16.23
+23.13%
-21.11
+31.59%
-30.86
-29.99%
-23.74
Depreciation Amortization Depletion
0.00
-100.00%
0.01
-55.39%
0.02
-41.33%
0.03
Depreciation
0.00
-100.00%
0.01
-55.39%
0.02
-41.33%
0.03
Depreciation And Amortization
0.00
-100.00%
0.01
-55.39%
0.02
-41.33%
0.03
Other Non Cash Items
0.74
-4.34%
0.77
—
-0.00
Stock Based Compensation
0.31
-90.53%
3.30
-38.93%
5.41
+14.30%
4.73
Change In Working Capital
-0.14
-11.52%
-0.12
-117.34%
0.70
-48.73%
1.36
Change In Receivables
—
0.00
-100.00%
0.03
+200.00%
-0.03
Changes In Account Receivables
—
0.00
-100.00%
0.03
+200.00%
-0.03
Change In Prepaid Assets
-0.05
-115.27%
0.33
+210.14%
-0.30
-2229.56%
0.01
Change In Payables And Accrued Expense
-0.33
-2.45%
-0.32
-133.87%
0.95
+280.04%
-0.53
Change In Payable
-0.33
-2.45%
-0.32
-133.87%
0.95
+280.04%
-0.53
Change In Account Payable
-0.33
-2.45%
-0.32
-133.87%
0.95
+280.04%
-0.53
Change In Other Working Capital
—
—
0.52
+228.61%
0.16
Change In Other Current Assets
0.24
-18.63%
0.30
-41.90%
0.52
+228.61%
0.16
Change In Other Current Liabilities
0.00
+100.40%
-0.43
+16.45%
-0.51
-129.10%
1.76
Investing Cash Flow
0.00
-100.00%
0.77
+1187.77%
-0.07
-19.22%
-0.06
Cash Flow From Continuing Investing Activities
0.00
-100.00%
0.77
+1187.77%
-0.07
-19.22%
-0.06
Net PPE Purchase And Sale
0.00
-100.00%
0.00
+589.94%
0.00
0.00
Purchase Of PPE
—
—
—
0.00
Sale Of PPE
0.00
-100.00%
0.00
+589.94%
0.00
0.00
Capital Expenditure
—
—
-0.07
-19.50%
-0.06
Net Intangibles Purchase And Sale
0.00
-100.00%
0.77
+1183.56%
-0.07
-19.50%
-0.06
Purchase Of Intangibles
—
0.00
+100.00%
-0.07
-19.50%
-0.06
Net Other Investing Changes
—
—
—
0.00
Financing Cash Flow
21.54
+79.32%
12.01
+13.39%
10.59
+164751.81%
0.01
Cash Flow From Continuing Financing Activities
21.54
+79.32%
12.01
+13.39%
10.59
+164751.81%
0.01
Net Common Stock Issuance
21.54
+79.32%
12.01
+13.39%
10.59
+164751.81%
0.01
Changes In Cash
6.23
+221.29%
-5.14
+63.87%
-14.22
+19.57%
-17.67
Beginning Cash Position
1.60
-76.23%
6.74
-67.85%
20.95
-45.76%
38.63
End Cash Position
7.83
+388.92%
1.60
-76.23%
6.74
-67.85%
20.95
Free Cash Flow
-15.31
+14.57%
-17.92
+27.76%
-24.81
-40.32%
-17.68
Common Stock Issuance
21.54
+79.32%
12.01
+13.39%
10.59
+164751.81%
0.01
Issuance Of Capital Stock
21.54
+79.32%
12.01
+13.39%
10.59
+164751.81%
0.01
Sale Of Intangibles
0.00
-100.00%
0.77
—
0.16
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category